Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

581

Participants

Timeline

Start Date

December 5, 2018

Primary Completion Date

December 4, 2023

Study Completion Date

March 5, 2024

Conditions
Anemia
Interventions
DEVICE

INTERCEPT

Pathogen reduced RBCs

DEVICE

Control

Conventional RBCs

Trial Locations (18)

15213

University of Pittsburgh Medical Center, Pittsburgh

19140

Temple, Philadelphia

22908

University of Virginia Health System, Charlottesville

27710

Duke University Health System, Durham

30308

Emory, Atlanta

32611

University of Florida, Gainesville

40356

University of Kentucky, Lexington

48109

University of Michigan, Ann Arbor

48202

Henry Ford Health System, Detroit

55905

Mayo-Rochester, Rochester

75390

University of Texas Southwestern, Dallas

77030

Houston Methodist, Houston

80045

University of Colorado Hospital, Aurora

90095

University of California Los Angeles, Los Angeles

94305

Stanford, Stanford

06610

Bridgeport Hospital, Bridgeport

06510

Yale New Haven Hospital, New Haven

02903

Rhode Island Hospital, Providence

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cerus Corporation

INDUSTRY